Healthcare Triangle, Inc. — fact timeline

Healthcare Triangle, Inc. entered into Platform Development Agreement with SecureKloud Technologies Limited (effective 2026-03-31).

“On April 7, 2026, Healthcare Triangle, Inc., a Delaware corporation (the “ Company ”), entered into a Platform Development Agreement (the “ Agreement ”) with SecureKloud Technologies Limited, an Indian corporation (“ SKL ”), as lead contractor, and Blockedge Technologies Inc., a subsidiary of SKL (“ Blockedge ”), as sub-contractor. The Agreement is made effective as of March 31, 2026.”

Healthcare Triangle, Inc. completed an acquisition involving CH 109, S.L., Ivan Montero Rebato and Maria Luisa Sanchez Fernandez.

“relating to the acquisition by Teyame AI Holdings Inc., the Company’s wholly owned subsidiary, of all of the outstanding equity interests of Teyamé 360 S.L. and Datono Mediación S.L. pursuant to that certain Share Purchase Agreement, dated January 22, 2026”

Healthcare Triangle, Inc. entered into Placement Agency Agreement with D. Boral Capital LLC (effective 2026-02-26).

“In connection with the Offering, the Company also entered into a placement agency agreement (the “Placement Agency Agreement”) with D. Boral Capital LLC (the “Placement Agent”), pursuant to which the Company paid the Placement Agent (i) a cash fee equal to 7% of the aggregate gross proceeds of the Offering, and (ii) reimbursed the Placement Agent for certain expenses and legal fees.”

Healthcare Triangle, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $3.95 million (effective 2026-02-26).

“On February 26, 2026, Healthcare Triangle, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a registered direct offering (A) an aggregate of 421,553 shares (the “Shares”) of common stock, par value $0.00001 per share (the “Common Stock”), of the Company, at an offering price of $5.81 per share, and (B) 260,000 pre-funded warrants (the “Pre-Funded Warrants”) in lieu of shares of Common Stock, at an offering price of $5.80999 (such registered direct offering, the “Offering”) for aggregate gross proceeds of approximately $3.95 million, before deducting Offering expenses payable by the Company, including the Placement Agent’s commissions and fees.”

Healthcare Triangle, Inc. entered into Share Purchase Agreement with Teyame AI Holdings Inc., Teyame AI LLC, CH 109, S.L., Ivan Montero Rebato, Maria Luisa Sanchez Fernandez valued at up to $50.0 million (effective 2026-01-22).

“On January 22, 2026, Healthcare Triangle, Inc., a Delaware corporation (the “ Company ”), entered into a Share Purchase Agreement (the “ Share Purchase Agreement ”), by and among (i) Teyame AI Holdings Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Buyer ”), (ii) the Company, (iii) Teyame AI LLC, a St Kitts and Nevis corporation (the “ Intermediary Seller ”), (iv) CH 109, S.L., a company incorporated in Spain (“ CH 109 ”), and (v) Ivan Montero Rebato and Maria Luisa Sanchez Fernandez (together with CH 109, S.L., the “ Original Sellers ”).”

Healthcare Triangle, Inc. incurred convertible notes of $7,500,000 with institutional investors at 18% per annum maturing November 20, 2026.

“Under the Purchase Agreement, the Company has agreed to issue 20% original issue discount senior unsecured convertible promissory notes (“Notes”) in an aggregate original principal amount of up to $15,000,000, which will be convertible into shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”). The closing of the first tranche was consummated on November 20, 2025, and the Company issued the initial Note for an aggregate original principal amount of $7,500,000 (the “Initial Tranche”). The Note issued in the Initial Tranche was sold to the Investors for a purchase price of $6,000,000, representing an original issue discount of twenty percent (20%), and matures on November 20, 2026.”

Healthcare Triangle, Inc. received a nasdaq compliance regained notice regarding shareholders (rules 5635(a)(1)).

“September 15, 2025, Healthcare Triangle, Inc. (the “Company”) received a letter from the Nasdaq Stock Market (“Nasdaq”) indicating that the Company had previously failed to comply with Nasdaq Listing Rule 5635(a)(1), which requires shareholder approval prior to the issuance of common stock representing 20% or more of the pre-transaction outstanding voting power or shares in connection with an acquisition. Nasdaq’s determination was based on the Company’s Form 8-K filed June 23, 2025, which disclosed that the Company agreed to issue approximately 345,622,120 shares of common stock (prior to adj”

Healthcare Triangle, Inc. completed an acquisition involving Niyama Healthcare, Inc. for $5.7 million (closed 2025-06-16).

“Price (as defined below) . The acquisition also closed on June 16, 2025. The total consideration for the acquisition, which is referred to herein as the “Purchase Price” is $5.7 million which includes: (1) $1.5 million in cash, of which $1.2 million is due on the Closing Date and $300,000 to be paid at the later of the satisfaction of certain withholding”

Sujatha Ramesh was appointed as executive director at Healthcare Triangle, Inc..

“the Board appointed Ms. Sujatha Ramesh as an executive director of the Company, along with their current role as the Chief Operating Officer of the Company.”

Shibu Kizhakevilayil resigned as director at Healthcare Triangle, Inc..

“Mr. Shibu Kizhakevilayil resigned as a director of the Company, effective immediately.”

David Ayanoglou was appointed as Chief Financial Officer at Healthcare Triangle, Inc..

“the Board of Directors (the “Board”) of the Company appointed Mr. David Ayanoglou to serve as the Company’s Chief Financial Officer, effective immediately.”

Thyagarajan Ramachandran resigned as Chief Financial Officer at Healthcare Triangle, Inc..

“On April 8, 2025, Mr. Thyagarajan Ramachandran informed the Company that they had decided to resign from their position as the Chief Financial Officer of the Company, effective April 10, 2025, along with the appointment of Mr. David Ayanoglou as the new Chief Financial Officer of the Company.”

Sujatha Ramesh was appointed as Chief Operating Officer at Healthcare Triangle, Inc..

“On March 18, 2025, the Board of Directors (the “Board”) of the Healthcare Triangle, Inc. (the “Company”) appointed Ms. Sujatha Ramesh to serve as the Company’s Chief Operating Officer, effective immediately.”

Healthcare Triangle, Inc. received a nasdaq noncompliance notice notice regarding shareholders.

“January 14, 2025, Healthcare Triangle, Inc. (the “ Company ”), received a letter from Nasdaq (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rules since it has not yet held an annual meet”

Anand Kumar resigned as Interim Chief Executive Officer at Healthcare Triangle, Inc..

“On September 4, 2024, Anand Kumar, the Interim Chief Executive Officer (“CEO”) of the Company, resigned from his role as CEO, effective immediately to pursue other professional opportunities.”

Healthcare Triangle, Inc. engaged M&K CPAS, PLLC as its auditor.

“On May 8, 2024, M&K CPAS, PLLC (“M&K”) was appointed as the new independent registered public accounting firm for Healthcare Triangle, Inc.”

Healthcare Triangle, Inc. dismissed BF Borgers CPA PC as its auditor.

“On May 3, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of Healthcare Triangle, Inc., a Delaware corporation (or the “Company”) approved the dismissal of BF Borgers CPA PC (“BF Borgers”) as the Company’s independent registered public accounting firm.”